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From transcriptional regulation to drugging the
cancer epigenome
James E Bradner
Abstract
Jay Bradner discusses the opportunities and
challenges for the study and therapeutic targeting of
the cancer epigenome, as well as innovative
approaches to drug discovery.
Introduction
J a yB r a d n e r( F i g u r e1 )i sa nA s s o c i a t eP r o f e s s o ri nt h e
Department of Medical Oncology at the Dana-Farber
Cancer Institute and the Department of Medicine at
Harvard Medical School. Additionally, Dr Bradner is
the Associate Director for the Center for the Science
of Therapeutics at the Broad Institute. The Bradner la-
boratory studies gene regulatory pathways, using chemical
biology approaches such as the development of new
chemical probes and innovative technologies to under-
stand the role of chromatin in cancer. Already, their study
of cancer gene regulatory pathways with chemistry has
translated three first-in-class molecules to human clinical
investigation as investigational cancer therapeutics.
How did your interest in transcriptional
regulation and epigenomics begin?
I became interested in gene regulation at Harvard College.
I worked in three laboratories during my undergraduate
education in biochemistry, with Profs Mark Ptashne,
Bruce Demple and Thomas O’Halloran (Northwestern
University). Each studied transcriptional biology, with
nuanced differences in focus. Each was a wonderful envir-
onment to be exposed to the rigor and scholarship of
basic research. In those early years, we were interested in
the allostery of heavy metals that bind the transcription
factors, sense toxins or environmental changes such as
mercury or superoxide, and effect novel mechanisms
of transactivation. Many years later, now in my own
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independent laboratory, we continue to study transcrip-
tion, but in human cells. We are particularly interested in
how chemical modulation of chromatin structure might
influence chromatin-dependent transcriptional signaling.
For sure, my laboratory’sp r e s e n tf o c u si nt r a n s c r i p t i o n a l
biology was influenced by the fortune of being exposed
to serious, mechanistic, basic biology at an early age. A
disease-specific interest in cancer emerged through my
subsequent training as an oncologist. Curious about
mechanisms of disease pathogenesis and the pharmacopoeia,
I attended the Pritzker School of Medicine at the University
of Chicago. There, and since then, it has become apparent
that cancer is fundamentally a heterogeneous disease of het-
erogeneous genetic alterations, the sum of which lead to
homogenous deregulation of a short list of master regulatory
transcription factors. Both the most frequently altered tumor
suppressor in cancer (TP53), and the most frequently acti-
vated oncogene (MYC), are master regulators of cell growth
and survival. In fact, almost all cancer growth signaling
pathways converge on MYC, which to date still lacks
direct-acting therapeutics. So we are highly motivated
to understand the function of MYC at regulatory regions,
and the deregulation of MYC via its own regulatory
elements.
Why do you think this area of research, of
drugging the cancer epigenome, is gaining
importance right now?
The field of epigenomics and transcriptional biology is
just exploding at the moment. It is a very exciting time,
when the basic biology and biochemistry of chromatin
structure and function can be appreciated at the genome
scale, but also with atomic resolution, through advances
in biochemistry and structural biology. Additionally, the
centrality of these altered transcriptional pathways in
cancer are clear from genome sequencing studies, which
have categorically identified alterations in gene regula-
tory proteins in nearly every type of human cancer. My
back of the envelope analysis of the somatic alterations
in cancer suggests that as many as 40% to 45% of all
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MYC alone may be somatically altered in more than
40% of aggressive malignancies [1].
This convergence has created an opportunity to de-
velop first-in-class molecules that disrupt these altered
transcriptional pathways. Innovations in protein and cel-
lular biochemistry arising from academia and within the
commercial sector have created powerful platform cap-
abilities to discover and optimize target-directed agents.
We have found genome-wide measurements of chromatin
structure, enhancer factor localization and RNA Polymer-
ase II response to be very powerful in understanding, con-
trasting and positioning new chemical entities targeting
chromatin-associated proteins.
Importantly, prototypical small molecules targeting the
so-called ‘readers’, ‘writers’ and ‘erasers’ of chromatin
are rapidly progressing through follow-up chemistry, re-
ceiving guidance from chemical biology and epigenomic
research, and translating to human clinical investigation.
So this is no longer aspirational. In the last 2 years, we
have already observed meaningful early activity among
several distinct classes of epigenome-targeted agents in
various solid and liquid forms of cancer. Hopefully for
our patients, this renaissance of chromatin biology will
bring a revolution in cancer medicine.
What epigenetic drugs have reached the clinic or
are in clinical development so far?
Small-molecule modulators of transcriptional pathways
have been in use in the clinic for many years. Tamoxifen
(targeting the estrogen receptor in breast cancer), bicalu-
tamide (targeting the androgen receptor in prostate can-
cer) and all-trans retinoic acid (targeting the retinoic
acid receptor fusion in acute promyelocytic leukemia)
have been among the most meaningful anticancer
agents for many years. These molecules bind and dis-
rupt the function of transcription factors, firmly valid-
ating transcriptional therapy in cancer. However, significant
challenges exist in discovery chemistry when moving
beyond factors such as these that possess ligand-binding
domains.
We therefore seek to develop molecules that modulate
accessory factors, known or previously unrecognized,
that are mechanistically required for master regulatory
transcription factor function. The field has already pro-
duced US Food and Drug Administration-approved drugs
targeting chromatin-associated enzymes, such as DNA
methyltransferases (for example, azacitidine, Celgene,
New Jersey, USA; and decitabine, MGI Pharma, Minnesota,
USA), and histone deacetylases (for example, Vorinostat,
Merck Research Laboratories, New Jersey, USA; Romidep-
sin, Celgene). The historic ease of targeting enzymes with
small molecule therapeutics has recruited significant effort
to inhibit the writers and erasers of chromatin, such as
lysine methyltransferases and lysine demethylases, respect-
ively. This second wave of small molecules includes inhibi-
tors of the DOT1L and EZH2 lysine methyltransferases,
inhibitors of the LSD1 lysine-specific demethylase, and in-
hibitors of the isocitrate dehydrogenase 2 enzyme (IDH2, a
metabolic enzyme which when mutated causes the produc-
tion of high concentrations of an epimetabolite that modu-
lates chromatin structure).
Broadly speaking, the majority of transcription factors
function by protein-protein interaction, and abrogating
such interactions has proven challenging in the discip-
line of ligand discovery. As an academic group, we were
comfortable approaching this challenge and created the first
inhibitors of epigenomic ‘reader’ proteins. Bromodomain-
containing proteins recognize acetylated lysine in active re-
gions of transcription, recruiting other co-activator proteins
to enforce transcription, as we have learned, of master regu-
latory transcription factors such as MYC. By displacing
the BET family of bromodomains with a first direct-acting
small-molecule inhibitor, JQ1, MYC transcription is im-
paired and MYC-addicted cancer cells die, senesce or
terminally differentiate. We hope this research opens a new
avenue of transcriptional drug discovery.
Overall, there is a rich pipeline of molecules in this
class at various stages of preclinical development, sug-
gesting that over the next decade this research – now in
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epigenomic pathways in cancer.
Which of these strategies do you think would be
the most promising for epigenetic cancer
therapy?
This is a very difficult question for the broader research
community to answer in the fullness of time. I do be-
lieve, as an academic chemical biologist, that empowering
the community with high-quality small-molecule probes
will allow directed science to tease out the killer oppor-
tunities for definitive therapeutic development. With that
said, these drugs must be developed wherever somatic
alterations of the target oncogene exist. IDH2 inhibitors
are naturally being developed for IDH2-mutant leukemia,
EZH2 inhibitors are being studied in EZH2-altered B-cell
lymphoma, and our BET inhibitors are actively being
studied in BET-rearranged lung cancer and BET-rearranged
head and neck cancer (so-called NUT midline carcinoma).
I would also advocate for the development of these
new compounds in context-specific dependencies, such
as DOT1L inhibition with MLL-rearrangement in pediatric
leukemia or BET inhibition with MYC or MYCN addiction.
What are the main challenges in drugging the
cancer epigenome as opposed to other molecular
targets?
A number of challenges exist. First, transcriptional
targets reside in the nucleus, which restricts the use of
therapeutic technologies significantly. Immunoglobulins,
peptides and nucleic acids lack the delivery properties to
target epigenomic pathways with the efficiency of deliv-
ery required for a cancer therapeutic. Therefore, a major
opportunity exists in the science of therapeutics to de-
velop classes of agents and modes of delivery that would
expand the arsenal of technologies available for disrupt-
ing gene regulatory pathways.
Second, gene regulatory pathways function largely
via macromolecular assembly. Interfacial protein bind-
ing surfaces are often extensive, lacking the hydropho-
bic invaginations into which small molecules efficiently
bind. Our positive experience targeting bromodomain-
histone interactions argues that disrupting transcrip-
tional complexes with high ligand efficiency is feasible,
and therefore argues for the detailed functional and
structural dissection of biophysical assemblies for sites
of interaction well-suited to small-molecule discovery
chemistry. In truth, these challenges are conceptual.
Groups comfortable with assuming the risk and hori-
zon of research required to develop transcriptional in-
hibitors will find success.
Third, we need much better measurements to guide the
use of these therapies. Where tumors possess putative
oncogenic drivers as somatic alterations, it is compelling
to study small molecules that target these oncogenic
alleles in patients that possess them. This is now obvious.
The development of small molecules targeting epigenomic
pathways will naturally benefit from new types of epige-
nomic biomarkers, such as for measurements of chromatin
structure and function that confirm target engagement, for
reporting on drug action and for predicting a favorable
therapeutic response. While this science is rapidly emer-
ging at the bench, few epigenomic biomarkers have yet to
reach the clinical interface.
Finally, we face a general challenge in the availability of
instructive prototype inhibitors. If you ask most disease
biologists, they will readily bemoan the lack of potent and
selective chemical probes for targets or pathways of inter-
est. Furthermore, when new drug molecules or probes are
created, there is typically a lack of immediate and unre-
stricted availability. I experienced this throughout my own
research training. So in our laboratory we have under-
taken a social experiment, of sorts, to make chemical
probes arising from our research freely and immediately
available to research laboratories, importantly without
restrictions on use or on amount of compound needed. It
is early days in this experiment, but already we have ob-
served an increase in publications around BET bromodo-
mains, many of which utilize the JQ1 chemical probe. We
plan to collect more sophisticated data, using relevant lit-
erature controls, so please stay tuned. Fundamentally, we
believe that a more open-source approach to drug discov-
ery could massively accelerate pre-clinical research time-
lines and expand the scope of research beyond even our
own hypotheses.
Other challenges exist such as a decline in federal
funding for research, challenges to efficient collabor-
ation between the biotechnology and pharmaceutical
industries, and others, but I firmly believe that this is a
time of incredible excitement and optimism. In our
field today, there is a palpable sense of progress and
impact.
How do you see this area of drug discovery
developing in the next 5 to 10 years?
The next 10 years will surely be marked by an acceleration
in epigenomic technology development, the mechanistic
dissection of somatic alterations in chromatin-associated
factors in cancer, the validation of new context-specific
targets, the early understanding of epigenomic drug resist-
ance, a proliferation of epigenomic research beyond
cancer (for example, inflammation and cardiovascular
disease), the discovery of new small-molecule modula-
tors of chromatin-associated factors and the definitive
development of second-wave epigenomic therapies. My
greatest hope for our field is that mechanistic insights and
clinical science successfully mature these new technolo-
gies into breakthrough therapies for patients.
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